Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1CNS 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 103Lymphoma, Large B-Cell, Diffuse 80Leukemia, Myeloid, Acute 74Multiple Myeloma 70Breast Neoplasms 69Lymphoma, Non-Hodgkin 62Lymphoma 61Leukemia, Lymphocytic, Chronic, B-Cell 53Burkitt Lymphoma 53Recurrence 51Lymphoma, Follicular 51Myelodysplastic Syndromes 50Lymphoma, B-Cell 47Leukemia 43Triple Negative Breast Neoplasms 40Lymphoma, Mantle-Cell 38Neoplasms 37Hodgkin Disease 34Melanoma 33Lymphoma, B-Cell, Marginal Zone 32Hematologic Neoplasms 31Leukemia, Myelogenous, Chronic, BCR-ABL Positive 29Neuroblastoma 28Ovarian Neoplasms 26Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 23Neoplasm Metastasis 22Leukemia, Biphenotypic, Acute 22Pancreatic Neoplasms 21Sarcoma 18Myeloproliferative Disorders 17

Interventions

fludarabine 1Cyclophosphamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Gaucher Disease × Cyclophosphamide × 1 year × Clear all
NCT03721068 2026-03-27

Study of CAR T-Cells Targeting the GD2 With IL-15+iCaspase9 for Relapsed/Refractory Neuroblastoma or Relapsed/Refractory Osteosarcoma

UNC Lineberger Comprehensive Cancer Center

Phase 1 Recruiting
18 enrolled
CNSSarcoma

Gaucher Disease, Neuroblastoma, Osteosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡